HansBiomed Corporation (042520) — Capital Reinvestment Ratio

Latest as of September 2025: 0.37x

HansBiomed Corporation (042520) has a Capital Reinvestment Ratio of 0.37x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩1.21 Billion) in capital expenditures (₩448.85 Million). See 042520 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.37x
Capex / Operating Cash Flow

Operating Cash Flow

₩1.21 Billion
KRW

Capital Expenditures

₩448.85 Million
KRW

Data as of

Sep 2025
Most recent filing

HansBiomed Corporation Capital Reinvestment Ratio (2012–2025)

This chart tracks HansBiomed Corporation's Capital Reinvestment Ratio across 10 annual periods. Check total reinvestment intensity of HansBiomed Corporation to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for HansBiomed Corporation (2012–2025)

Year-by-year Capital Reinvestment Ratio for HansBiomed Corporation from 2012 to 2025. For live market cap and broader valuation context, see HansBiomed Corporation (042520) market capitalisation.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 5.52x ₩318.34 Million ₩1.76 Billion ▲ +243.2%
2024 1.61x ₩1.76 Billion ₩2.83 Billion ▲ +31.3%
2020 1.23x ₩5.75 Billion ₩7.05 Billion ▼ -39.3%
2019 2.02x ₩7.71 Billion ₩15.56 Billion ▲ +368.7%
2018 0.43x ₩5.20 Billion ₩2.24 Billion ▼ -81.5%
2017 2.33x ₩5.60 Billion ₩13.05 Billion ▲ +33.1%
2015 1.75x ₩3.47 Billion ₩6.07 Billion ▼ -70.9%
2014 6.01x ₩2.06 Billion ₩12.39 Billion ▲ +92.3%
2013 3.13x ₩2.33 Billion ₩7.29 Billion ▲ +1750.5%
2012 0.17x ₩1.50 Billion ₩253.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow